Empagliflozin - Latest Advances

New potential treatment options for syndrome of inappropriate antidiuresis.

Journal: Best practice & research. Clinical endocrinology & metabolism

Published: October 11, 2025

Does Age Matter? SGLT2 Inhibitors in Older Adults With Heart Failure.

Journal: Circulation. Heart failure

Published: October 10, 2025

SGLT-2 Inhibitors After Acute Coronary Syndrome: A Preventive Approach for Heart Failure-Related Complications: A Meta-Analysis.

Journal: American journal of therapeutics

Published: October 09, 2025

Liraglutide and empagliflozin alleviate diabetic cardiomyopathy by reducing oxidative stress and inflammation.

Journal: Gaceta medica de Mexico

Published: October 08, 2025

Teneligliptin and empagliflozin attenuate ferroptosis-mediated acute tubular injury.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: October 03, 2025

Drug hypersensitivity: When systemic symptoms and pustules converge

Journal: Revista alergia Mexico (Tecamachalco, Puebla, Mexico : 1993)

Published: October 02, 2025

A clever evaluation of the antidiabetic medications linagliptin and empagliflozin in bulk and spiked urine samples.

Journal: Bioanalysis

Published: September 29, 2025

Empagliflozin Attenuates Diabetic Cardiomyopathy via Inhibiting Cardiomyocyte Ferroptosis Through the USP7/NRF2 Signaling Pathway.

Journal: Antioxidants & redox signaling

Published: September 26, 2025

Bullous pemphigoid induced by linagliptin: a case series of 17 patients in a rare disease referral center.

Journal: Italian journal of dermatology and venereology

Published: September 24, 2025

A case of Rabson-Mendenhall syndrome treated with empagliflozin combined with metformin

Journal: Zhonghua er ke za zhi = Chinese journal of pediatrics

Published: September 17, 2025

Correction: Unravelling the mechanism by which vildagliptin and linagliptin inhibit pyroptosis in lung injury through the NLRP3 inflammatory pathway in type 1 diabetic rats.

Journal: Scientific reports

Published: September 15, 2025

Effectiveness of SGLT2 Inhibitors in Improving Functional Capacity and Reducing Hospitalizations in Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review of Randomized Controlled Trials.

Journal: Cureus

Published: September 15, 2025

Filters

New potential treatment options for syndrome of inappropriate antidiuresis.

New potential treatment options for syndrome of inappropriate antidiuresis.

Does Age Matter? SGLT2 Inhibitors in Older Adults With Heart Failure.

Does Age Matter? SGLT2 Inhibitors in Older Adults With Heart Failure.

SGLT-2 Inhibitors After Acute Coronary Syndrome: A Preventive Approach for Heart Failure-Related Complications: A Meta-Analysis.

SGLT-2 Inhibitors After Acute Coronary Syndrome: A Preventive Approach for Heart Failure-Related Complications: A Meta-Analysis.

Liraglutide and empagliflozin alleviate diabetic cardiomyopathy by reducing oxidative stress and inflammation.

Liraglutide and empagliflozin alleviate diabetic cardiomyopathy by reducing oxidative stress and inflammation.

Teneligliptin and empagliflozin attenuate ferroptosis-mediated acute tubular injury.

Teneligliptin and empagliflozin attenuate ferroptosis-mediated acute tubular injury.

Drug hypersensitivity: When systemic symptoms and pustules converge

Drug hypersensitivity: When systemic symptoms and pustules converge

A clever evaluation of the antidiabetic medications linagliptin and empagliflozin in bulk and spiked urine samples.

A clever evaluation of the antidiabetic medications linagliptin and empagliflozin in bulk and spiked urine samples.

Empagliflozin Attenuates Diabetic Cardiomyopathy via Inhibiting Cardiomyocyte Ferroptosis Through the USP7/NRF2 Signaling Pathway.

Empagliflozin Attenuates Diabetic Cardiomyopathy via Inhibiting Cardiomyocyte Ferroptosis Through the USP7/NRF2 Signaling Pathway.

Bullous pemphigoid induced by linagliptin: a case series of 17 patients in a rare disease referral center.

Bullous pemphigoid induced by linagliptin: a case series of 17 patients in a rare disease referral center.

A case of Rabson-Mendenhall syndrome treated with empagliflozin combined with metformin

A case of Rabson-Mendenhall syndrome treated with empagliflozin combined with metformin

Correction: Unravelling the mechanism by which vildagliptin and linagliptin inhibit pyroptosis in lung injury through the NLRP3 inflammatory pathway in type 1 diabetic rats.

Correction: Unravelling the mechanism by which vildagliptin and linagliptin inhibit pyroptosis in lung injury through the NLRP3 inflammatory pathway in type 1 diabetic rats.

Effectiveness of SGLT2 Inhibitors in Improving Functional Capacity and Reducing Hospitalizations in Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review of Randomized Controlled Trials.

Effectiveness of SGLT2 Inhibitors in Improving Functional Capacity and Reducing Hospitalizations in Heart Failure With Preserved Ejection Fraction (HFpEF): A Systematic Review of Randomized Controlled Trials.